Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors

被引：12

作者：

Bainbridge, Jacquelyn L. ^{[1
,2
]}

Page, Robert Lee, II ^{[3
,4
]}

Ruscin, J. Mark ^{[3
]}

机构：

[1] Univ Colorado, Dept Clin Pharm, Aurora, CO 80045 USA

[2] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA

[3] Univ Colorado, Dept Clin Pharm, Denver, CO 80262 USA

[4] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80262 USA

来源：

NEUROLOGIC CLINICS | 2008年 / 26卷 / 03期

关键词：

D O I：

10.1016/j.ncl.2008.05.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

A critical enzyme in neurotransmitter metabolism is monoamine oxidase (MAO). MAO occurs in two isoforms, MAO-A and MAO-B. MAO inhibitors are classified as selective for a particular subtype of MAO or nonselective and can be reversible or irreversible. Nonselective MAO inhibitors originally were studied as antidepressants. Newer MAO-B selective irreversible inhibitors are indicated for use in treatment of Parkinson's disease. MAO-B inhibitors offer modest antiparkinsonian effects, as they do not inhibit brain MAO-A effectively at the dose used in treating parkinson's disease. In this article, the mechanism of action of MAO-B inhibitors, their potential neuroprotective effects, interactions such as the cheese reaction, and serotonin syndrome are discussed.

引用

页码：S85 / +

页数：13

共 47 条

[1] Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells [J].

Abu-Raya, S ;

Tabakman, R ;

Blaugrund, E ;

Trembovler, V ;

Lazarovici, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 434 (03) :109-116

[2] Differential subcellular location of mitochondria in rat serotonergic neurons depends on the presence and the absence of monoamine oxidase type B [J].

Arai, R ;

Karasawa, N ;

Kurokawa, K ;

Kanai, H ;

Horiike, K ;

Ito, A .

NEUROSCIENCE, 2002, 114 (04) :825-835

[3] Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline [J].

Bar Am, O ;

Amit, T ;

Youdim, MBH .

NEUROSCIENCE LETTERS, 2004, 355 (03) :169-172

[4] The serotonin syndrome [J].

Boyer, EW ;

Shannon, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1112-1120

[5] MONOAMINE-OXIDASE INHIBITORS - SAFETY AND EFFICACY ISSUES [J].

BROWN, CS ;

BRYANT, SG .

DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (03) :232-235

[6] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[7]

COHEN G, 1988, NEUROLOGY, V38, P130

[8]

COLLINS G G S, 1970, Nature (London), V225, P817, DOI 10.1038/225817a0

[9] Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline [J].

deMarcaida, J. Antonelle ;

Schwid, Steven R. ;

White, William B. ;

Blindauer, Karen ;

Fahn, Stanley ;

Kieburtz, Karl ;

Stern, Matthew ;

Shoulson, Ira .

MOVEMENT DISORDERS, 2006, 21 (10) :1716-1721

[10]

DEXTER DT, 1987, LANCET, V2, P1219

← 1 2 3 4 5 →